Process for the preparation of...

Details Process for the preparation of... Process for the preparation of...

2006-07-11

2006-07-11

Coleman, Brenda (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Unsubstituted hydrocarbyl chain between the ring and the -c-...

C540S573000, C540S574000, C514S221000

Reexamination Certificate

active

07074921

ABSTRACT:
Methods for the synthesis of benzodiazepine compounds having farnesyl protein transferase inhibitory activity.

REFERENCES:
patent: 5141851 (1992-08-01), Brown et al.
patent: 6011029 (2000-01-01), Ding et al.
patent: 6100395 (2000-08-01), Chen et al.
patent: 6218375 (2001-04-01), Raghavan et al.
patent: 6455523 (2002-09-01), Ding et al.
patent: 6458783 (2002-10-01), Ding et al.
patent: 6537988 (2003-03-01), Lee
patent: 2002/0169313 (2002-11-01), Gao et al.
patent: 0 675 112 (1995-10-01), None
patent: 7-112930 (1995-05-01), None
patent: WO 95/09001 (1995-04-01), None
patent: WO 95/10514 (1995-04-01), None
patent: WO 95/10515 (1995-04-01), None
patent: WO 95/10516 (1995-04-01), None
patent: WO 99/18951 (1999-04-01), None
CA 136:355252, 2002.
Hunt et al., Discovery of (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), Journal of Medicinal Chemistry, vol. 43, No. 20, pp. 3587-3595, Oct. 5, 2000.
Rose et al., Preclinical Antitumor Activity of BMS-214662, a Highly Apoptotic and Novel Farnesyltransferase Inhibitor, Cancer Research, vol. 61, No. 20, pp. 7507-7517, Oct. 15, 2001.
Buchwald, H. et al., “Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis”, Surgery, vol. 88, No. 4, pp. 507-516 (1980).
Clarke, S., “Protein Isoprenylation and Methylation at Carboxyl-Terminal Cysteine Residues”, Annu. Rev. Biochem., vol. 61, pp. 355-386 (1992).
During, M.J. et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization”, Ann. Neurol., vol. 25, pp. 351-356 (1989).
Glenn, J.S. et al., “Identification of a Prenylation Site in Delta Virus Large Antigen”, Science, vol. 256, pp. 1331-1333 (1992).
Goodson, J.M., Chapter 6: “Dental Applications”, Medical Applications of Controlled Release, vol. II: Applications and Evaluation, CRC Press, Inc., publ., Langer, R.S. et al., eds., pp. 115-138 (1984).
Graham, S.L. et al., “Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase”, J. Med. Chem., vol. 37, pp. 725-732 (1994).
Howard III, M.A. et al., “Intracerebral drug delivery in rats with lesion-induced memory deficits”, J. Neurosurg., vol. 71, pp. 105-112 (1989).
James, G.L. et al., “Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells”, Science, vol. 260, pp. 1937-1942 (1993).
James, G.L. et al., “PxF, a Prenylated Protein of Peroxisomes”, The Journal of Biological Chemistry, vol. 269, No. 19, pp. 14182-14190 (1994).
Kohl, N.E. et al., “Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas inrastransgenic mice”, Nature Medicine, vol. 1, No. 8, pp. 792-797 (1995).
Kohl, N.E. et al., “Protein farnesyltransferase inhibitors block the growth ofras-dependent tumors in nude mice”, Proc. Natl. Acad. Sci. USA, vol. 91, pp. 9141-9145 (1994).
Kohl, N.E. et al., “Selective Inhibition ofras-Dependent Transformation by a Farnesyltransferase Inhibitor”, Science, vol. 260, pp. 1934-1937 (1993).
Langer, R., “New Methods of Drug Delivery”, Science, vol. 249, pp. 1527-1533 (1990).
Langer, R. et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review”, JMS-Rev. Macromol. Chem. Phys., C23, No. 1, pp. 61-126 (1983).
Langer, R.S. et al., eds., Medical Applications of Controlled Release, vol. I: Classes of Systems, and vol. II: Applications and Evaluation, CRC Press, Inc., publ. (table of contents) (1984).
Levy, R.J. et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate”, Science, vol. 228, pp. 190-192 (1985).
Lowy, D.R. et al., “Function and Regulation of RAS”, Annu. Rev. Biochem., vol. 62, pp. 851-891 (1993).
Reiss, Y. et al., “Sequence requirement for peptide recognition by rat brain p21rasprotein farnesyltransferase”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 732-736 (1991).
Saudek, C.D. et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”, The New England Journal of Medicine, vol. 321, No. 9, pp. 574-579 (1989).
Schafer, W.R. et al., “Protein Prenylation: Genes, Enzymes, Targets, and Functions”, Annu. Rev. Genet., vol. 30, pp. 209-237 (1992).
Sefton, M.V., “Implantable Pumps”, CRC Critical Reviews in Biomedical Engineering, vol. 14, No. 3, pp. 201-240 (1987).
Smolen, V.F. et al., eds., Controlled Drug Bioavailability, vol. 1: Drug Product Design and Performance, John Wiley & Sons, publ., pp. xiii (table of contents) (1984).
Smolen, V.F. et al., eds., Controlled Drug Bioavailability, vol. 2: Bioavailability Methodology and Regulation, John Wiley & Sons, publ., pp. xiii (table of contents) (1984).
Willumsen, B.M. et al., “The p21rasC-terminus is required for transformation and membrane association”, Nature, vol. 310, pp. 583-586 (1984).
Chen, B., et al., “Novel triethylsilane mediated reductive N-alkylation of amines: improved synthesis of 1-(4-imidazolyl)methyl-4-sulfonylbenzodiazepines, new farnesyltransferase inhibitors”, Tetrahedron Letters, vol. 42, pp. 1245-12-46, (2001).

Affiliated with

Also associated with

Rating

Process for the preparation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for the preparation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for the preparation of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3611795